FDA grants breakthrough device designation to digital therapeutic for schizophrenia

The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.
According to a Click press release, CT-155 is a novel software accessible on mobile devices that is being studied as an adjunct to standard of care pharmaceutical therapy for schizophrenia.
Currently available antipsychotic medications for schizophrenia are indicated for positive symptoms, such as hallucinations, disorganized speech and behavior agitation. However, negative

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.